Scholarlink

<p><i>Streptococcus pneumoniae (S. pneumoniae)</i> is a leading cause of respiratory infections, with increasing antibiotic resistance posing a major challenge. While gold nanoparticles (AuNPs) functionalised with antibiotics have been explored, their impact on bacterial adherence and invasion remains underexplored. This study presents a vancomycin-conjugated AuNP formulation designed to enhance antibacterial efficacy and prevent <i>S. pneumoniae</i> colonisation. The nano-formulation was characterised using UV-Vis spectroscopy and TEM, confirming successful conjugation and a uniform spherical size of 23 ± 1 nm. Minimum inhibitory concentration (MIC) assays demonstrated a significant reduction in the required concentrations of AuNPs (from 512 to 32 µg ml<sup>-1</sup>) and vancomycin (from 0.5 to 0.125 µg ml<sup>-1</sup>) compared to their individual use. Unlike previous studies that focused solely on bacterial viability, our work demonstrates that the nano-antibiotic effectively inhibits bacterial adherence and invasion in human alveolar epithelial cells (A549). Mechanistically, vancomycin weakens the bacterial cell wall, facilitating AuNP penetration, membrane disruption, and oxidative stress-induced bacterial death. This dual-action mechanism not only enhances bactericidal effects but also prevents bacterial colonisation—an aspect not extensively explored in prior studies. Toxicity assays confirmed that the formulation was non-toxic to A549 cells, supporting its potential for clinical applications. These findings highlight the synergistic antibacterial and anti-infective properties of vancomycin-functionalised AuNPs, offering a promising strategy to combat <i>S. pneumoniae</i> infections while mitigating antibiotic resistance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Gold nanoparticles functionalised with vancomycin enhance antibacterial activity and inhibit Streptococcus pneumoniae adherence and invasion in alveolar cells

  • 期刊论文

  • 发表日期：

    2025年8月15日

查看全文
  • Edgar Augusto Ortiz-Benitez,
  • Diego Jeovani Huerta-Flores,
  • Norma Velázquez-Guadarrama,
  • Marco Antonio González-López,
  • José de Jesús Olivares-Trejo

摘要

Streptococcus pneumoniae (S. pneumoniae) is a leading cause of respiratory infections, with increasing antibiotic resistance posing a major challenge. While gold nanoparticles (AuNPs) functionalised with antibiotics have been explored, their impact on bacterial adherence and invasion remains underexplored. This study presents a vancomycin-conjugated AuNP formulation designed to enhance antibacterial efficacy and prevent S. pneumoniae colonisation. The nano-formulation was characterised using UV-Vis spectroscopy and TEM, confirming successful conjugation and a uniform spherical size of 23 ± 1 nm. Minimum inhibitory concentration (MIC) assays demonstrated a significant reduction in the required concentrations of AuNPs (from 512 to 32 µg ml-1) and vancomycin (from 0.5 to 0.125 µg ml-1) compared to their individual use. Unlike previous studies that focused solely on bacterial viability, our work demonstrates that the nano-antibiotic effectively inhibits bacterial adherence and invasion in human alveolar epithelial cells (A549). Mechanistically, vancomycin weakens the bacterial cell wall, facilitating AuNP penetration, membrane disruption, and oxidative stress-induced bacterial death. This dual-action mechanism not only enhances bactericidal effects but also prevents bacterial colonisation—an aspect not extensively explored in prior studies. Toxicity assays confirmed that the formulation was non-toxic to A549 cells, supporting its potential for clinical applications. These findings highlight the synergistic antibacterial and anti-infective properties of vancomycin-functionalised AuNPs, offering a promising strategy to combat S. pneumoniae infections while mitigating antibiotic resistance.